Head-to-head: Potent hepatitis B antivirals compared

The drugs appear similarly effective in reducing risk of liver cancer, studies show

Tenofovir and entecavir appear to be equally effective in reducing risk of hepatocellular carcinoma (HCC) and all-cause mortality in people with hepatitis B over five years, a ‘real-world’ study suggests.

CT scan liver cancer

In the longest follow-up to date, more than 3000 patients with hepatitis B attending the Catholic University of Korea’s liver clinics were included in a retrospective analysis, with 1439 on tenofovir and 1583 taking entecavir.

No statistically significant difference was found between five-year cumulative incidence rates